Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the complement ...

On the menu today: Immigration hawks and Trump administration fans are not going to like what I have to say today, but everybody needs to hear it anyway. Read on. Back in September, the Supreme Court ...